Opioid abuse
disease diseaseOn this page
Summary
Opioid abuse (MONDO:0001225) is a disease and 52 clinical trials. Top therapeutic interventions include dextromethorphan, alprazolam, and buprenorphine. A subtype of substance abuse — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 52
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | opioid abuse |
| Mondo ID | MONDO:0001225 |
| DOID | DOID:11206 |
| ICD-10-CM | F11.1 |
| ICD-11 | 912365674 |
| SNOMED CT | 5602001 |
| UMLS | C0029095 |
| MedGen | 508001 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of substance abuse. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › substance-related disorder › substance abuse › opioid abuse
Related subtypes (7): antidepressant type abuse, hallucinogen abuse, alcohol abuse, amphetamine abuse, cocaine abuse, barbiturate abuse, phencyclidine abuse
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 52.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 32 |
| PHASE4 | 6 |
| PHASE2 | 6 |
| PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 2 |
| EARLY_PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03783702 | PHASE4 | COMPLETED | Pain Control Following Sinus Surgery |
| NCT03857139 | PHASE4 | WITHDRAWN | Opioids and Smoking Cessation |
| NCT04033562 | PHASE4 | TERMINATED | The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis |
| NCT04495374 | PHASE4 | TERMINATED | Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy |
| NCT05363436 | PHASE4 | SUSPENDED | Opioid Reduction Toolkit Reduces Opioids Prescribed and Consumed |
| NCT05644587 | PHASE4 | TERMINATED | Novel Induction to Buprenorphine/Naloxone |
| NCT01189097 | PHASE3 | UNKNOWN | Combined Therapy of Methadone and Dextromethrophan |
| NCT03394911 | PHASE3 | UNKNOWN | Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction |
| NCT05006079 | PHASE2 | RECRUITING | Opioid/Benzodiazepine Polydrug Abuse: Aim 3 |
| NCT00499746 | PHASE1/PHASE2 | COMPLETED | The Discriminative Effects of Tramadol in Humans |
| NCT00699010 | PHASE2 | COMPLETED | Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse |
| NCT01030406 | PHASE2 | COMPLETED | Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users |
| NCT01136356 | PHASE1/PHASE2 | COMPLETED | A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals |
| NCT01395784 | PHASE2 | COMPLETED | Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone |
| NCT01740414 | PHASE2 | COMPLETED | Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers |
| NCT04177706 | PHASE2 | COMPLETED | Ketamine for the Treatment of Opioid Use Disorder and Depression |
| NCT03143855 | PHASE1 | COMPLETED | Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder |
| NCT04018664 | PHASE1 | COMPLETED | Oral Abuse Potential Study of Nalbuphine |
| NCT03822962 | EARLY_PHASE1 | TERMINATED | Pain Management Following Sinus Surgery |
| NCT04883983 | EARLY_PHASE1 | WITHDRAWN | OLP to Manage Pain in TJA: A Feasibility Study |
| NCT03773523 | Not specified | RECRUITING | Neuromodulation and Cognitive Training in Opioid Use Disorder |
| NCT05706311 | Not specified | ACTIVE_NOT_RECRUITING | Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool |
| NCT05711056 | Not specified | RECRUITING | Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated Treatment |
| NCT06651333 | Not specified | RECRUITING | fMRI and Opioid Abstinence |
| NCT07466784 | Not specified | RECRUITING | CEDRN: Opioid Registry |
| NCT07586917 | Not specified | NOT_YET_RECRUITING | Optimizing Pregnancy and Treatment Interventions for Moms 3.0 |
| NCT07587359 | Not specified | NOT_YET_RECRUITING | A Unique, Co-Designed Family-Based Therapy |
| NCT01632982 | Not specified | UNKNOWN | Mobile Psychosocial Interventions for MMT Clients |
| NCT01881802 | Not specified | UNKNOWN | Study of Opioid Immunosuppressive Effects |
| NCT01884233 | Not specified | COMPLETED | Cell Phone Technology Targeting ART Adherence and Drug Use |
| NCT02804152 | Not specified | COMPLETED | Program for Pain & Prescription Opioid Use in Pregnancy |
| NCT03241771 | Not specified | COMPLETED | Impact of Direct Outreach to Expand Access to Naloxone in the Context of Standing Orders |
| NCT03377855 | Not specified | COMPLETED | Addressing Origins of the Opioid Epidemic by Improving Prescribing for Opioid-Naive Patients |
| NCT03570099 | Not specified | UNKNOWN | Naloxone Treatment in Skåne County - Effect on Drug-related Mortality and Overdose-related Complications |
| NCT03611335 | Not specified | COMPLETED | A Pragmatic Trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) Model for Engaging Patients in Opioid Use Disorder Treatment |
| NCT03684681 | Not specified | COMPLETED | The Navigator Trial |
| NCT03743493 | Not specified | COMPLETED | PCORnet Opioid Surveillance Study |
| NCT03834025 | Not specified | COMPLETED | Nudges and Incentives to Enhance the Opioid Treatment Workforce |
| NCT03936985 | Not specified | COMPLETED | Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool |
| NCT03992079 | Not specified | TERMINATED | A Multimodal Enhanced Recovery Program in Anorectal Surgery |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DEXTROMETHORPHAN | 4 | 3 |
| ALPRAZOLAM | 4 | 1 |
| BUPRENORPHINE | 4 | 1 |
| HYDROMORPHONE | 4 | 1 |
| IBUDILAST | 4 | 1 |
| KETAMINE HYDROCHLORIDE | 4 | 1 |
| LORCASERIN | 4 | 1 |
| NALBUPHINE | 4 | 1 |
| NALOXONE | 4 | 1 |
| NICOTINE | 4 | 1 |
| OXYCODONE | 4 | 1 |
| PREGABALIN | 4 | 1 |
| CHEMBL452845 | 0 | 1 |